Genome & Co is Biotechnology in South Korea that focus on Co is business. Founded in 2015. They cover business area such as Genome, Co, dietary supplement, cosmeceutical, new drug, its product pipeline, immunooncology therapeutic supplement, treatment, immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer, obesity, diabete, cosmetic, acne, atopic dermatitis, Virto fertilization medicine.
2015
( 11 years old in 2026 )
Co Is
-
B-8F, Silicon Park, 35, Pangyo-ro 255beon-gil
Bundang-gu
Seongnam, Gyeonggi-do 13486
South Korea
Private
GenomeCodietary supplementcosmeceuticalnew drugits product pipelineimmunooncology therapeutic supplementtreatmentimmuno-oncologylung cancercolorectal cancerstomach cancerbreast cancerpancreatic cancerobesitydiabetecosmeticacneatopic dermatitisVirto fertilization medicine
* We use standard office opening hours in near Genome & Co's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Genome & Co is Biotechnology business from South Korea that founded in 2015 (11 years old in 2026), Genome & Co business is focusing on Co Is.
Genome & Co headquarter office and corporate office address is located in B-8F, Silicon Park, 35, Pangyo-ro 255beon-gil Bundang-gu Seongnam, Gyeonggi-do 13486 South Korea.
Genome & Co was founded in South Korea.
In 2026, Genome & Co is currently focus on Co is sector.
Above is snippet of Google Trends for "Co is" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Genome & Co, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
